Wednesday, January 18, 2012

$3.58 Million Gift Will Forward Scientific Advances For Mesothelioma Research, One Of The Most Difficult To Treat Cancers


The UH Cancer Center has received a $3.58 million gift from an anonymous donor to support the mesothelioma research of Dr. Michele Carbone, director of the UH Cancer Center. Carbone and colleagues, who include Drs. Haining Yang and Giovanni Gaudino, have made a series of recent scientific breakthroughs that will lead to new ways to prevent and treat the disease.

"This generous gift is critical to support our efforts to generate discoveries that will aid in the prevention of mesothelioma and the development of new therapies," said Dr. Carbone. Mesothelioma is a cancer of the cells that line the chest and abdominal cavities. It results in one of the most aggressive types of tumors, and current median survival from diagnosis is just twelve months. Exposure to airborne asbestos or erionite particles increases one's risk of developing mesothelioma.


The gift is the second largest in UH Cancer Center history. "Mesothelioma is a serious public health problem," said Dr. Virginia Hinshaw, Chancellor of UH Manoa. "We're proud that Dr. Carbone's team is leading the world in this area of discovery. This gift validates their efforts and will help them remain at the forefront of thoracic oncology research."


Dr. Carbone and colleagues have studied mesothelioma for more than a decade. Significant findings have come from studies conducted in the villages of Capadoccia, a region of Turkey. Dubbed "death villages," nearly 50% of the area's residents develop and die of mesothelioma. The epidemic is caused by exposure to a fiber called erionite that is even more potent than asbestos in causing mesothelioma. Erionite is a naturally occurring mineral found in rock formations and homes built of rock material in the region. The team's findings led to a response from the Turkish government that included building the villagers new homes and a regional health center to conduct treatment.


Dr. Carbone and collaborators will conduct a clinical trial co-sponsored by the Early Detection Research Network of the U.S. National Cancer Institute and the Turkish Ministry of Health to validate serum biomarkers they discovered for the early detection of mesothelioma.


This past winter, Dr. Carbone reported new findings describing potential erionite exposure in the U.S. (Nature, Dec. 16, 2010). Collaborating with scientists at the Environmental Protection Agency and the National Institutes of Health, they found evidence of erionite in rock materials used to pave roads in North Dakota and other states. Public health concerns have been raised and the team's examination continues in partnership with the EPA. Findings from a new detailed study were presented at a recent scientific meeting and are pending publication in a leading scientific journal. The National Institutes of Health has planned a conference this fall to discuss potential public health issues related to erionite exposure."


Source:
Kellie Tormey
University of Hawaii Cancer Center

Article adapted by Medical News Today from original press release.
Visit our asbestos / mesothelioma section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

View the original article here

1st International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma

The UCLA Mesothelioma Research Program is sponsoring the 1st International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma (MPM) at the Sheraton Hotel in Santa Monica, California. This unique one-day symposium will take place on Saturday, May 21st from 8:00 a.m. to 5:00 p.m.

The course will be led by Dr. Robert Cameron, MD, FACS, Director of the Mesothelioma Research Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans' Administration Medical Center, and a long-time advocate for lung-sparing surgery.


The seminar's distinguished international faculty includes both Mr. Tom Treasure, MD and Mr. David A Waller, MD, who will discuss the recent results announced from the Mesothelioma and Radical Surgery (MARS) Trial conducted in the U.K. The program will feature additional experts in the fields of surgery, radiation, chemotherapy and pulmonary medicine. The symposium was designed primarily for physicians needing continuing medical education (CME) credit but other interested parties may attend.


For a brochure on the seminar and to enroll online, go here.


Source:
UCLA Mesothelioma Research Program

Article adapted by Medical News Today from original press release.
Visit our conferences section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

UCLA Mesothelioma Research Program. "1st International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma." Medical News Today. MediLexicon, Intl., 9 May. 2011. Web.
16 Jan. 2012. APA

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, January 17, 2012

Novel Anti-Mesothelioma Strategy

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Temsirolimus, a kinase inhibitor, blocks the action of mammalian target of rapamycin (mTOR), a protein that regulates cell growth, which can slow tumor growth. It's used to treat advanced renal cell carcinoma.


But researchers in Austria have found that temsirolimus also may slow the growth of malignant pleural mesothelioma cells. Mesothelioma, a cancer that is usually caused by exposure to asbestos and may not appear until 30 to 50 years after exposure, frequently resists chemotherapy and radiation treatment.


The researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic, or growth-stopping, effect on all mesothelioma cells. However, mesothelioma cells that were resistant to cisplatin, a widely used chemotherapy drug, showed hypersensitivity against temsirolimus.


That suggests that mTOR inhibitors like temsirolimus might be a promising treatment strategy either in combination with chemotherapy or as second-line treatment after chemotherapy failure.


"Malignant mesothelioma is a severe human malignancy characterized by a very bad prognosis, with a mean patient survival time of less than one year," said Professor Walter Berger, PhD, of the Institute of Cancer Research at the Medical University of Vienna. "This unacceptable situation is mainly caused by late diagnosis combined with a distinct resistance to all forms of systemic therapy available so far. Mesothelioma is frequently caused by asbestos exposure and unfortunately - based on the long latency period - the incidence peak lies, despite the ban on asbestos, still ahead. Consequently, novel therapeutic options for this devastative disease are urgently needed.


"In our preclinical study, published in the JTO, we were able to demonstrate that inhibition of the major oncogene mTOR is active against human mesothelioma especially after development of chemotherapy resistance both in vitro and in vivo," Berger said. "These results suggest the initiation of clinical trials involving mTOR inhibitors as a novel anti-mesothelioma strategy."


The study was supported by the Medical Scientific Fund of the Mayor of the City of Vienna, Initiative Krebsforschung of the Medical University Vienna, and a Wyeth/Pfizer research grant.


Source:
Renée McGaw
International Association for the Study of Lung Cancer

Article adapted by Medical News Today from original press release.
Visit our asbestos / mesothelioma section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Renée McGaw. "Novel Anti-Mesothelioma Strategy." Medical News Today. MediLexicon, Intl., 1 May. 2011. Web.
16 Jan. 2012. APA

 



View the original article here

 
Design by Wordpress Theme | Bloggerized by Free Blogger Templates | free samples without surveys